Biosimilars Latam – Mexico 2018 is a unique and effective meeting point to share the information and experience Latin America’s Pharmaceutical Industry needs to develop a dynamic and thriving biosimilars market.
Join us in Mexico and trigger a quantum leap in Latin American Healthcare!
Industry Executives from Latam
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Business Development
The Influence of the 257 Mexican Standard into the Biologic’s Market
Panel Discussion: Interchangeability Real Scenario
Biosimilars, The Mexican Industry Approach
With the new government and in order to achieve universal coverage, Mexico must focus on local production of Biotechnology Drugs, increasing its National Integration percentage and implement consolidated purchases for the health system
Panel: Current position of Regulatory Agencies after new government
Clinical Trials required for Biosimilars?
Interview: Industry Leaders and Their Strategy to Increase Biosimilar’s Access in the Region
Becton Dickinson and Company
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories.
As a leading provider of medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies, GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications and services.
The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83 billion euros according to preliminary figures. At the end of 2019, more than 9,000 people work at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.
Codigo 46 is a Mexican company focused on DNA analysis, providing the necessary tools for individuals and institutions looking for information about DNA.
They use Global Screeing Array Chip in 24 format, it is a panel of biomarkers detecting genetic variations, which are selected by world wide experts and some of them are selected specificly to the mexican population.